Orexo AB (publ)

OTC-ORXOY
OTCMKTS
Healthcare Drug Manufacturers - Specialty & Generic
Global Rank
#28445
Country Rank
#365
Market Cap
72.22 M
Price
2.04
Change (%)
22.83%
Volume
200

Orexo AB (publ)'s latest marketcap:

72.22 M

As of 06/03/2026, Orexo AB (publ)'s market capitalization has reached $72.22 M. According to our data, Orexo AB (publ) is the 28445th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 72.22 M
Revenue (ttm) 1.87 M
Net Income (ttm) 54.78 M
Shares Out 0
EPS (ttm) 1.57
Forward PE 0.00
Ex-Dividend Date n/a
Earnings Date 07/16/2026
Market Cap Chart
Data Updated: 06/03/2026

Orexo AB (publ)'s yearly market capitalization.

Orexo AB (publ) has seen its market value drop from $600.48 M to $72.22 M since 2014, representing a total decrease of 87.97% and an annual compound decline rate (CAGR) of 16.92%.
Date Market Cap($) Change (%) Global Rank
06/03/2026 $72.22 M -3.54% 28445
12/30/2025 $113 M 106.69% 46359
12/30/2024 $54.67 M 3.62% 46049
12/29/2023 $52.76 M -15.15% 44400
12/30/2022 $62.18 M -52.51% 42720
12/30/2021 $130.93 M -37.43% 40811
12/30/2020 $209.26 M -10.52% 37721
12/30/2019 $233.86 M 3.14% 35158
12/28/2018 $226.74 M 30.42% 33858
12/29/2017 $173.85 M 20.36% 32430

Company Profile

About Orexo AB (publ)

Orexo AB (publ) is a specialty pharmaceutical company focused on developing and commercializing innovative pharmaceuticals and digital therapies. The company operates in the United States, European Union, and internationally.

Key Products

  • Zubsolv tablets – Treatment for opioid use disorder.
  • Abstral – Breakthrough pain relief for cancer patients.
  • Edluar – A solution for insomnia treatment.

Pipeline Developments

  • OX124 – Targeting opioid overdose.
  • OX125 – Rescue medication for opioid overdose.
  • OX640 – Emergency treatment for allergic reactions.
  • OX-MPI – Therapy for endometriosis.

Digital Therapies

  • deprexis – Digital treatment for depression.
  • vorvida – Alcohol management program.
  • modia – Digital support for opioid use disorder.

Collaborations

Orexo has partnered with Abera Bioscience AB to develop nasal powder vaccines using the AmorphOX technology.

Company Background

Founded in 1994, Orexo AB (publ) is headquartered in Uppsala, Sweden.

Frequently Asked Questions

  • What is Orexo AB (publ)'s (OTC-ORXOY) current market cap?
    As of 06/03/2026, Orexo AB (publ) (including the parent company, if applicable) has an estimated market capitalization of $72.22 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
  • Orexo AB (publ) global market capitalization ranking is approximately 28445 as of 06/03/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Research Tools

Copyright © 2026. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.